|
The Munich-based biopharmaceutical company, WILEX AG, has signed a
licensing agreement with Ion Beam Applications (IBA) for the worldwide
marketing, distribution and sales of its diagnostic product candidate
Redectane (CA9-SCAN), a radiolabelled antibody visualized by PET that
is currently in a pivotal phase III registration trial.
|
|
more...
|
Previous